Pharma

TreeFrog Therapeutics Leases 13,488 Square Feet at Cambridgeport Labs

January 6, 2025

MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

December 18, 2024

Tasca Therapeutics Launches with $52 Million Series A Financing

December 10, 2024

THIS WEEK'S STORIES

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

January 27, 2025

Timothy G. Ferris, MD, MPH, Former NHS England and Mass General Executive, Joins Red Cell Partners to Lead Healthcare Practice

January 21, 2025

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

January 21, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform

Most Read

Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software

Olink® Reveal Seamlessly Connects Genomics and Proteomics, Empowering Researchers to Uncover the Dynamic Mechanisms Underlying Biology

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

Timothy G. Ferris, MD, MPH, Former NHS England and Mass General Executive, Joins Red Cell Partners to Lead Healthcare Practice

EDITOR PICKS

TreeFrog Therapeutics Leases 13,488 Square Feet at Cambridgeport Labs

MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

Tasca Therapeutics Launches with $52 Million Series A Financing

THIS WEEK'S STORIES

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

Timothy G. Ferris, MD, MPH, Former NHS England and Mass General Executive, Joins Red Cell Partners to Lead Healthcare Practice

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

POPULAR CATEGORY

ABOUT US

FOLLOW US